Dana–Farber Cancer Institute

In Boston, Massachusetts, the Dana–Farber Cancer Institute is a comprehensive cancer treatment and research facility. Dana-Farber is a founding member of the Dana–Farber/Harvard Cancer Center, Harvard's National Cancer Institute-designated Comprehensive Cancer Center, and one of Harvard Medical School's 15 clinical affiliates and research institutes. Dana-Farber is currently ranked as the world's third-best cancer hospital. Among its past and present faculty are two Nobel laureates in Physiology or Medicine. Among Dana-research Farber's accomplishments is the development of the highly successful Gleevec treatment for chronic myeloid leukemia.

The Dana–Farber/Harvard Cancer Center is the nation's largest Comprehensive Cancer Center designated by the National Cancer Institute (NCI). DF/HCC, founded in 1997, is an inter-institutional research enterprise that brings together all of the Harvard-affiliated community's cancer research efforts. The Cancer Center's primary goal is to foster collaborative interactions and translational research that will lead to new approaches to cancer prevention, diagnosis, and treatment. Members of the DF/HCC pool their extensive experience and renowned expertise in all aspects of cancer research. They conduct research in disease site- and discipline-based research programs that span institutional and scientific boundaries.

Detailed information:

Add: 450 Brookline Avenue, Boston, MA 02215

Hotline: 617-632-3000

Website: dana-farber.org

Facebook: facebook.com/danafarbercancerinstitute